Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

321 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology.
Ramesh S, Dyer E, Pomaville M, Doytcheva K, Dolezal J, Kochanny S, Terhaar R, Mehrhoff CJ, Patel K, Brewer J, Kusswurm B, Naranjo A, Shimada H, Cipriani NA, Husain AN, Pytel P, Sokol EA, Cohn SL, George RE, Pearson AT, Applebaum MA. Ramesh S, et al. Among authors: cohn sl. NPJ Precis Oncol. 2024 Nov 8;8(1):255. doi: 10.1038/s41698-024-00745-0. NPJ Precis Oncol. 2024. PMID: 39511421 Free PMC article.
Outcomes of patients with intermediate-risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531.
Voeller J, Katzenstein HM, Naranjo A, Tenney SC, Chen L, London WB, Handler MH, Schmidt ML, Shimada H, Hogarty MD, Gastier-Foster J, Park JR, Cohn SL, Maris JM, Bagatell R, Twist CJ. Voeller J, et al. Among authors: cohn sl. Pediatr Blood Cancer. 2025 Jan;72(1):e31407. doi: 10.1002/pbc.31407. Epub 2024 Nov 6. Pediatr Blood Cancer. 2025. PMID: 39502014
Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.
Brown EG, Adkins ES, Mattei P, Hoffer FA, Wootton-Gorges SL, London WB, Naranjo A, Schmidt ML, Hogarty MD, Irwin MS, Cohn SL, Park JR, Maris JM, Bagatell R, Twist CJ, Nuchtern JG, Davidoff AM, Newman EA, Lal DR. Brown EG, et al. Among authors: cohn sl. J Pediatr Surg. 2025 Jan;60(1):161896. doi: 10.1016/j.jpedsurg.2024.161896. Epub 2024 Sep 6. J Pediatr Surg. 2025. PMID: 39317567 Free article.
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531.
Barr EK, Naranjo A, Twist CJ, Tenney SC, Schmidt ML, London WB, Gastier-Foster J, Adkins ES, Mattei P, Handler MH, Matthay KK, Park JR, Maris JM, Desai AV, Cohn SL. Barr EK, et al. Among authors: cohn sl. Pediatr Blood Cancer. 2024 Aug;71(8):e31089. doi: 10.1002/pbc.31089. Epub 2024 May 31. Pediatr Blood Cancer. 2024. PMID: 38822537
Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation.
Pomaville M, Chennakesavalu M, Wang P, Jiang Z, Sun HL, Ren P, Borchert R, Gupta V, Ye C, Ge R, Zhu Z, Brodnik M, Zhong Y, Moore K, Salwen H, George RE, Krajewska M, Chlenski A, Applebaum MA, He C, Cohn SL. Pomaville M, et al. Among authors: cohn sl. Cell Rep. 2024 May 28;43(5):114165. doi: 10.1016/j.celrep.2024.114165. Epub 2024 Apr 30. Cell Rep. 2024. PMID: 38691450 Free PMC article.
Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study.
Friedman DN, Goodman PJ, Leisenring WM, Diller LR, Cohn SL, Howell RM, Smith SA, Tonorezos ES, Wolden SL, Neglia JP, Ness KK, Gibson TM, Nathan PC, Turcotte LM, Weil BR, Robison LL, Oeffinger KC, Armstrong GT, Sklar CA, Henderson TO. Friedman DN, et al. Among authors: cohn sl. J Natl Cancer Inst. 2024 Jun 7;116(6):885-894. doi: 10.1093/jnci/djae062. J Natl Cancer Inst. 2024. PMID: 38460547
321 results